Financial Guidance for FY2027

The company provided consolidated financial guidance for FY2027:

  • Expected revenue: At least ₹1,550 crore, representing growth of over 20% compared to FY2026
  • Expected PAT: At least ₹178 crore, representing growth of over 50% compared to FY2026
  • Expected PAT margin: 11.4%, representing a margin inflection of at least 200bps compared to FY2026

The majority of FY2027 growth is expected to be driven by the company's base businesses of in vitro diagnostics and renewable energy & LED. A material step-up in contribution is expected from FY2028 onward from the sickle cell testing business and the medical devices business (comprising Onco Spectra and TB Truth), which commences meaningful commercialization in FY2028.

Proposed Business Restructuring

The Board proposes to demerge the company's renewable energy and LED business into a separate entity, Lords Shakti Power Limited:

  • The company will hold 60% in the resulting entity
  • Existing shareholders will receive shares in proportion to their holdings
  • The scheme is proposed to be filed by March 2027
  • The demerger will allow the energy business to pursue its capital programme while enabling healthcare and diagnostics businesses to be valued on their own fundamentals
  • Lords Shakti Power Limited will enter the power transmission business via transformer manufacturing

CAR-T Cell Therapy Expansion

The company is set to enter into an exclusive India agreement with a leading global CAR-T manufacturer:

  • Will establish laboratory and treatment capability across five centers in India
  • First two centers planned at Mumbai and Bangalore
  • Targeted commencement by March 2027
  • Intends to offer treatment at substantially lower price points than currently available

International Subsidiary Establishments

Lords Mark Industries UK Limited:

  • Established subsidiary in the United Kingdom
  • First Indian company to register in the UK following the India-UK Free Trade Agreement
  • Targeted operational from January 2027
  • Will operate its own pathology laboratory supplied entirely with company-manufactured test kits, analyzers and biochemistry reagents
  • Will additionally supply diagnostic materials to other UK laboratories
  • NHS approval application submitted

Lords Mark Industries Swiss Limited:

  • Under process to establish subsidiary in Switzerland
  • Same business plan as UK entity: captive pathology laboratory and wholesale supply to local laboratories
  • Extends regulated-market presence into continental Europe

Healthcare Delivery Expansion

Lords Mark Medicine Limited:

  • Established subsidiary to enter healthcare delivery through owned oncology hospitals in tier-2 cities
  • Addressing market where approximately 70% of districts lack comprehensive cancer care centers
  • Radiotherapy capacity stands at 0.6 machines per million population against WHO norm of 1-3
  • Programme commences with two pilot hospitals of approximately 70 beds each at Vapi and Solapur
  • Targeted opening by March 2027
  • Proposed funding through debt raise of approximately ₹200 crore in December 2026
  • Feasibility and city-selection study by leading global consulting firm underway
  • Expected to provide captive channel for company's diagnostics and medical device businesses

Dialysis Centre Network:

  • Proposes to establish 50 dialysis centers across India by March 2027
  • Operated from rented premises with 3-5 company-owned RENALOS dialysis machines per center
  • Rented-premises model limits capital requirement to equipment and fit-out
  • In-house manufacture allows network equipment at cost
  • Shifts dialysis business from equipment sales to recurring, session-based service revenue

Regulatory Approvals and Product Development

OneDNA Genomic Testing Platform:

  • Completed patient trials
  • Received approval from Indian Council of Medical Research (ICMR)
  • Application to Central Drugs Standard Control Organisation (CDSCO) under process
  • Extends diagnostics portfolio into genomics-led preventive and personalized healthcare

Biomescan Analytics Platform:

  • Received manufacturing license for In Vitro Diagnostic Software (Software as a Medical Device - SaMD) under Medical Devices Rules, 2017
  • Licensed as wellness and health-information tool for preventive healthcare and early health risk assessment
  • First and only company in India to receive such license (as previously intimated on August 10, 2026)

Management Commentary

Mr. Sachidanand Upadhyay, Managing Director, stated: "Lord's Mark today stands at the most important inflection point in its history. Over the past decade we have built profitable, scaled businesses in diagnostics and renewable energy, the foundations of which now fund our next chapter. The guidance we have issued reflects the strength of our existing operations, with top-line growth of at least 20% and PAT growth of at least 50%. The subsequent announcements are what we build on top of them: cancer care reaching India's rural districts, advanced CAR-T therapy at affordable prices for Indian patients, and Indian-made diagnostics serving laboratories from the UK to Switzerland. Healthcare in India is moving from scarcity to access, and Lord's Mark intends to be one of the companies that makes that happen."